CXO firms report strong order backlogs, expect full-year growth

The signal here is order backlogs rather than current revenue — a forward-looking indicator that pharma R&D spending is loosening after a soft stretch, with out-licensing activity cited as the accelerant. That matters most for the CXO names themselves and their biotech clients, whose pipeline funding ultimately feeds these bookings. The open question is whether backlog converts on schedule: fourth-quarter delivery execution and the durability of out-licensing momentum are the variables worth watching, since companies' own growth expectations rest on both holding up.